Cardiac resynchronization therapy with defibrillator therapy was associated with a greater increase in relative wall thickness compared with implantable cardioverter-defibrillator therapy.
After adjustment for cardiovascular risk factors, diabetes was seen as independent risk factor for atrial fibrillation in a cross-sectional study in Shenyang, China.
Patients with atrial fibrillation who late gadolinium enhancement >35% had more recurrent atrial fibrillation, regardless of baseline persistence.
Patients with idiopathic dilated cardiomyopathy vs those with known heart disease had better outcomes in catheter ablation for atrial fibrillation.
Potentially pathogenic genetic variants in arrhythmia susceptibility genes are not associated with an abnormal phenotype in an unselected population.
Substrate-based ablation found superior to ablation targeting only clinical and mappable ventricular tachycardias in patients with ischemic cardiomyopathy.
Data from the SchlaHF registry demonstrate a high prevalence of sleep-disordered breathing in stable chronic heart failure patients, especially those who were older males with high BMIs.
Five cases of probable interaction, including severe renal impairment, between the anticoagulant acenocoumarol and levofloxacin were described in patients with atrial fibrillation.
Left atrial functional improvement independently predicated atrial fibrillation-free survival after cardiac resynchronization therapy.
Endurance exercise may accelerate the pathogenesis of arrhythmogenic ventricular cardiomyopathy.
